# Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

> **NCT03865212** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 12 (actual)

## Conditions studied

- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Choroid Melanoma
- Metastatic Melanoma
- Metastatic Mucosal Melanoma
- Metastatic Uveal Melanoma
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Unresectable Melanoma

## Interventions

- **DRUG:** Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1

## Key facts

- **NCT ID:** NCT03865212
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-12
- **Primary completion:** 2025-10-12
- **Final completion:** 2025-10-12
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Lack of funding; lack of objective response
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03865212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03865212, "Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03865212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*